拟再发10亿可交债，凯盛新材成华邦系“提款机”？

Core Viewpoint - The company Huabang Health is frequently issuing exchangeable bonds to monetize its holdings in Kaisheng New Materials, with the latest issuance planned for up to 1 billion yuan to repay debts, reflecting a strategy to manage financial pressures while reducing its stake in Kaisheng New Materials [1][4][5]. Group 1: Bond Issuance and Financial Strategy - Huabang Health plans to issue non-public exchangeable bonds not exceeding 1 billion yuan, with a term of up to 3 years, to repay debts [1][4]. - This is not the first issuance tied to Kaisheng New Materials; earlier in April, the company issued 600 million yuan in exchangeable bonds with an initial conversion price of 14.78 yuan per share [1][6]. - The stock price of Kaisheng New Materials has surged over 95% this year, leading to a conversion yield exceeding 90% for bondholders, prompting them to convert their bonds into shares [1][7]. Group 2: Impact on Shareholding and Financial Health - Following the bond conversions, Huabang Health's shareholding in Kaisheng New Materials decreased from 1.67 billion shares to 1.27 billion shares, reducing its ownership percentage from 39.75% to 30.13% [1][7]. - The conversion of bonds allowed Huabang Health to clear 600 million yuan in interest-bearing debt without cash outflow, effectively lowering its debt-to-asset ratio and alleviating financial pressure [7]. Group 3: Acquisition and Goodwill Issues - The company has faced significant goodwill impairment due to acquisitions, with a total of 1.283 billion yuan in goodwill impairment provisions from the acquisition of Baisheng Pharmaceutical between 2022 and 2024, severely impacting net profit [2][11]. - In 2024, Huabang Health reported a revenue of 11.665 billion yuan, a slight increase of 0.60%, but a net loss of 299 million yuan, marking its first annual loss since going public [11]. Group 4: Broader Context of Huabang System - The Huabang system, which includes Huabang Health, Kaisheng New Materials, Lijiang Co., and Yingtai Biology, has a total market value exceeding 30 billion yuan [8][9]. - The aggressive acquisition strategy has led to financial strain, with Huabang Health's short-term liabilities totaling 4.505 billion yuan against cash and financial assets of only 4.033 billion yuan [9][10]. - The company's high dividend payout policy has raised concerns, with cash dividends exceeding net profits in recent years, indicating potential sustainability issues [11].